SEC Form 4 · accession 0001209191-17-036145
Sierra Oncology, Inc. · SRRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Estes
Director
Period of report
May 25, 2017
Accepted (ET)
May 30, 2017 · 4:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001290149
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $1.20 | May 25, 2017 | A | 50,000 | A | — | May 25, 2027 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1Stock options were granted in connection with the reporting person's appointment to the issuer's board of directors on April 10, 2017.
- F2The option vests as to 8.333% of the total shares monthly, beginning on June 25, 2017, with 100% of the total shares vested and exercisable on May 25, 2018, subject to the reporting person's provision of service to the issuer on each vesting date.